Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23897412 | 0.91 | NPC1 (0.34) | NPC1POLBRAB9ABLMCYP2D6 | |
| SCHEMBL23869881 | 0.76 | NPC1 (0.41) | NPC1POLBRAB9ABLMCYP2D6 | |
| SCHEMBL23869876 | 0.72 | NPC1 (0.34) | NPC1POLBRAB9A | |
| SCHEMBL19963501 | 0.65 | NAALAD2 (0.44) | CYP2D6PPARAMEN1KMT2AHIF1A | |
| SCHEMBL23854636 | 0.65 | MCHR1 (0.49) | NPC1RAB9ACYP2D6MEN1KMT2A | |
| SCHEMBL23869882 | 0.62 | SMN1; SMN2 (0.43) | KMT2A | |
| SCHEMBL25113352 | 0.61 | ACLY (0.37) | PPARATDP1 | |
| SCHEMBL25497339 | 0.60 | GBA1 (0.43) | NPC1POLBRAB9A | |
| SCHEMBL23074633 | 0.59 | ACLY (0.36) | PPARATDP1 | |
| SCHEMBL21011730 | 0.59 | ACLY (0.36) | PPARATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | NPC1 1523/4885POLB 4302/4885RAB9A 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.